An International Comparison of Teratogen Consultation Systems (Motherisk and Toranomon) and a Proposed Optimal System with an Innovative Risk Calculation Formula *
Restricted accessResearch articleFirst published online October, 1996
An International Comparison of Teratogen Consultation Systems (Motherisk and Toranomon) and a Proposed Optimal System with an Innovative Risk Calculation Formula *
The Canadian Motherisk Program is so well-organized that it can be regarded as a representative teratogen consultation system outside of Japan. The Toranomon Hospital's system is a similar system within Japan. By studying various characteristics of the two systems an optimal system was proposed with an innovative risk calculation formula. In the proposed optimal system, one should consider such factors as system follow-up, versatile computer back-up, global coverage of people, easy access to the system, well-controlled documentation, sufficient and up-to-date information collection, financial support by health insurance, manpower back-up in different specialties, and security protection. An innovative risk calculation formula is a product of risk points of the drug itself and administration-time risk points of the particular drug in question.
MurdochLALumL. Timeliness of receipt of manufacturers' new product information. Can J Hosp Pharmacy.1992;45:79–85.
2.
GoddardH. Watching the medicine go down. Can Pharma J.1990;123:486–487, 506.
3.
PellegriniEKorenG. The Motherisk program—pregnancy and drug counselling. On Contin Practice.1988;15:2–6.
4.
MageeLAKorenG. The use of teratogen information services for research: assessment of reliability of data entry. Reprod Toxicol.1994;8:419–424.
5.
KorenGGrahamKFeihenbaumAEinarsonT. Evaluation and counseling of teratogenic risks: the Motherisk approach. J Clin Pharmacol.1993;33: 405–411.
6.
SergeantKAKeithM. Formalized drug information training in North American colleges of pharmacy. ASHP Midyear Clinical Meeting. 1990;25:P-37R.
7.
MurdochLA. Computer use in Canadian drug information centers. Can J Hasp Pharmacy.1990;43: 13–15.
8.
JohnsonNDupuisLL. Quality assurance audit of a drug information service. Can J Hosp Pharmacy.1989;42:57–61.
9.
HlynkaJN. Getting the biggest bang for your buck. Can Pharma J.1988;121:746–750.
10.
RepchinskyCGodboutLTierneyM. Quality assurance audit for a regional and a hospital drug information service. Can J Hosp Pharmacy.1988;41:267–269.
11.
GoddardH. Breaking out of the mold. Can Pharma J.1988;121:556–557.
12.
SteevesRAColoumbeDDelongS. CSHP guidance for drug information filing systems, August 1986. Can J Hosp Pharmacy.1987;40:35–36.
13.
RantucciMJSegalHJ. Over-the-Counter medication: Outcome and effectiveness of patient. J Social Administ Pharmacy.1986;3:81–91.
14.
MaulhotCGiacoma-DahlNS. Drug information services in Quebec: Determination of community and hospital pharmacists' needs. Drug Intell Clin Pharm.1987;21:57–63.
15.
BruynsD. Improving communication between the pharmaceutical industry and drug information centers. Can Pharma J.1986;119:352–355.
16.
Anonymous. Hospital association takes lead in coordinating drug information services in Ontario. Am J Hosp Pharmacy.1985;42:2389.
17.
HayashiMNakadateMOsadaTIshibeTTanakaSMaekawaASofuniTNakataYKanohNHashibaS. A fact database for toxicological data at the National Institute of Hygienic Sciences. Japan Environ Health Perspect.1991;96:57–60.
18.
KlopmanGDimayugaML. Computer Automated Structure Evaluation (CASE) of the teratogenicity of retinoids with the aid of a novel geometry index. J Comput Aided Mol.1990;4:117–130.
19.
FriersonMRMielachFAKochharDM. Computer-automated structure evaluation (CASE) of retinoids in teratogen bioassays. Fund Appl Toxicol.1990; 14:408–428.
20.
VialTMaguinVPhamEDescotesJ. The monitoring of teratogens. The methodology of a follow-up study. Therapie.1989;44:453–455.
21.
KallenB. Search for teratogenic risks with the aid of malformation registries. Teratol.1987;35:47–52.
22.
WatkinsonWPBriceMARobinsonKS. A computer-assisted electrocardiographic analysis system: methodology and potential application to cardiovascular toxicology. Toxicol Environ Health.1985; 15:713–727.
23.
LawrenceRGLe MoguenPAndennahMNachbaurJStadlerJ. An interactive system for management of toxicology and teratology studies in laboratory animals. Med Inf.1985;10:107–113.
24.
KatohHHayashiM. Drugs taken during pregnancy and their effect on fetus (1)—foundation of the pregnancy drug consultation service at the Toranomon Hospital. J Japanese Pharma Assoc.1993;45:1007–1011.
25.
KatohHHayashiM. Drugs taken during pregnancy and their effect on fetus (1)—risk evaluation method for drugs taken during pregnancy. J Japanese Pharma Assoc.1993;45:1185–1193.
26.
KatohHHayashiM. Drugs taken during pregnancy and their effect on fetus (1)—drugs whose fetal effects should be carefully watched. J Japanese Pharma Assoc.1993;45:1323–1330.
27.
MatsumieSYamaguchiY. Book of drugs on which caution should be paid during pregnancy. Tokyo, Japan; Asahi-shuppan:1988.
